Page Menu

Basal Cell Carcinoma Clinical Trials

African American man looking into Basal Cell Carcinoma Clinical Trials

Oncologists conduct basal cell carcinoma clinical trials to determine the benefits of promising new treatments. These studies also allow patients to access some of the newest, most innovative therapies for basal cell carcinoma, long before those treatments are made available in other settings.

Moffitt Cancer Center’s Cutaneous Oncology Program has one of the most robust clinical trials programs in the region. As a National Cancer Institute-designated Comprehensive Cancer Center, we have tested novel skin cancer treatments such as:

  • Intralesional therapy, a treatment in which anti-cancer medications are injected directly into the tumor site. In past studies, this treatment produced notable tumor shrinkage in more than half of the participants.
  • Adoptive cell therapy, a treatment in which tumor-specific T-cells are administered to a patient, with the intent of triggering the body’s natural immune response. Moffitt is one of just three cancer centers in the entire nation to have clinical protocol for using T-cell therapy to treat skin cancer.
  • Immunotherapy, another treatment that is designed to program the body’s immune system to attack the tumor. This therapy has been the subject of many promising clinical trials for other cancers, and its effectiveness for skin cancer is currently being investigated.

These trials may be especially beneficial for patients with difficult-to-treat cancers, such as basal cell carcinoma that has metastasized to other parts of the body. Even for non-metastatic carcinomas, which are highly responsive to conventional therapies, clinical trials can help researchers determine the best order in which to prescribe certain treatments (for example, surgery before radiation therapy or vice versa.) 

Patients can participate in Moffitt Cancer Center’s basal cell carcinoma clinical trials without requesting a referral from their primary physicians. To learn which of our trials are most appropriate for your needs and whether you may qualify, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.

calledFromCancerPage=True - substr=
testProtocol=

Open Clinical Trials:

Showing of 50

CLINICAL TRIAL 18989

A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 19327

A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients with Metastatic Melanoma or Non-small Cell Lung Cancer with Untreated Brain Metastases

Disease Site: Non small cell lung cancer, Brain and Nervous System, Lung, Melanoma, skin, Gliomas

View Trial Details

CLINICAL TRIAL 19441

Pilot Study of Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 19495

A Multicenter, Randomized, Double Blinded, Placebo Controlled, Phase 3 trial of Adjuvant Avelumab (anti PDL1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases

Disease Site: Merkel cell carcinoma (neuroendocrine skin cancer), Other Skin

View Trial Details

CLINICAL TRIAL 19748

Phase II Randomized Trial of Radiotherapy with Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients with Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN Trial)

Disease Site: Head & Neck, Squamous Cell Carcinoma (SCC), Lip, Oral Cavity and Pharynx, Other Skin

View Trial Details

CLINICAL TRIAL 19967

A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma

Disease Site: Skin, Other Skin

View Trial Details

CLINICAL TRIAL 20040

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Disease Site: Merkel cell carcinoma (neuroendocrine skin cancer), Other Skin

View Trial Details

CLINICAL TRIAL 20162

Phase 1 Trial of Intralesional Immunotherapy with IFx-Hu2.0 Vaccine in Patients with Advanced Merkel Cell Carcinoma or Cutaneous Squamous Cell Carcinoma

Disease Site: Melanoma, skin, Merkel cell carcinoma (neuroendocrine skin cancer), Other Skin, Skin, Squamous Cell Carcinoma (SCC)

View Trial Details

CLINICAL TRIAL 20270

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors (IOV-COM-202)

Disease Site: Lung, Melanoma, skin, Non small cell lung cancer

View Trial Details

CLINICAL TRIAL 20313

Neoadjuvant Immunotherapy with Intratumoral Tavokinogene Telseplasmid (Tavo) plus Electroporation in Combination with Intravenous Nivolumab in Patients with Operable Locally- Regionally Advanced Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 20490

Keystroke: A Randomized Phase II Study of Pembrolizumab (Keytruda) Plus Stereotactic Re-irradiation versus SBRT Alone For Locoregionally Recurrent or Second Primary Head and Neck Carcinoma

Disease Site: Other Skin

View Trial Details

CLINICAL TRIAL 20494

A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 20562

A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma

Disease Site: Other Skin, Skin, Squamous Cell Carcinoma (SCC)

View Trial Details

CLINICAL TRIAL 20641

A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 20731

Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Disease Site: Other Skin, Squamous Cell Carcinoma (SCC)

View Trial Details

CLINICAL TRIAL 20773

Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma

Disease Site: Merkel cell carcinoma (neuroendocrine skin cancer), Other Skin

View Trial Details

CLINICAL TRIAL 20794

Neoadjuvant Cemiplimab in Stage I-II Merkel Cell Carcinoma: Safety and Biomarker Analysis

Disease Site: Other Skin

View Trial Details

CLINICAL TRIAL 20854

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Disease Site: Melanoma, skin, Other Skin

View Trial Details

CLINICAL TRIAL 20904

A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in Braf-V600 Mutant Melanoma with Brain Metastases

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 20956

A Two-Part, Phase 1a/B, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, Safety and Efficacy Of PF-07284890 (ARRY-461) In Participants With BRAF V600-Mutant Solid Tumors With And Without Brain Involvement

Disease Site: Any Site, Brain and Nervous System, Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Skin, Brain metastasis, Gliomas

View Trial Details

CLINICAL TRIAL 21080

A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors (DRAGON)

Disease Site: Any Site, Lung, Melanoma, skin, Urinary Bladder

View Trial Details

CLINICAL TRIAL 21112

Phase 2 Study of Axitinib + Ipilimumab in Advanced Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 21163

A Phase 1/2 Study of Regn7075 (Egfrxcd28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors

Disease Site: Anus, Breast, Cervix, Colon, Esophagus, Kidney, Lip, Oral Cavity and Pharynx, Lung, Other Digestive Organ, Other Female Genital, Other Male Genital, Other Skin, Other Urinary, Pancreas, Prostate, Stomach

View Trial Details

CLINICAL TRIAL 21179

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects with Advanced Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 21180

A First-in-Human, Two-Part, Open-Label, Clinical Study to Assess the Safety, Tolerability and Activity of Intravenous Doses of ICT01 as Monotherapy and in Combination with an Immune Checkpoint Inhibitor, in Patients with Advanced-Stage, Relapsed/Refractory Cancer (EVICTION Study)

Disease Site: Any Site, Breast, Colon, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Ovary, Prostate, Stomach, Urinary Bladder

View Trial Details

CLINICAL TRIAL 21239

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 21344

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Melanoma (Morpheus-Melanoma)

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 21573

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients with Hepatic Dominant Ocular Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 90015

Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Disease Site: Breast, Lung, Melanoma, skin, Ovary, Pancreas, Urinary Bladder

View Trial Details

CLINICAL TRIAL 20256

CemiplimAb Survivorship Epidemiology (CASE) Study

Disease Site: Squamous Cell Carcinoma (SCC), Other Skin

View Trial Details

CLINICAL TRIAL 21183

The EDUCATE Initiative A Multimodal Campaign to Enhance Provider-Patient Awareness of CTCL Disparities in Skin of Color

Disease Site: Other Skin

View Trial Details

CLINICAL TRIAL 19950

Linking the Skin and Gut Microbiome to Immunosuppression in Skin Cancer

Disease Site: Other Skin

View Trial Details

CLINICAL TRIAL 21125

MElanoma Research Lymph Node Prediction Implementation National_001 (MERLIN_001)

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 50401

Creation of Cell Lines and Corresponding DNA and RNA Analysis from Acral Lentiginous Malignant Melanoma

Disease Site: Melanoma, skin

View Trial Details